U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease

FDA’s PDUFA goal date is November 1, 2026If approved, mitapivat is positioned to become the first oral PK activator for patients with sickle cell ...
ISPreview UK

Broadband Altnets Spar with Ofcom Over Openreach UK Copper Line Retirement

The UK telecom regulator's proposal in their Telecoms Access Review 2026 (TAR), which sought to adopt a different approach to ...
The Garden Magazine on MSN

Backyard gardener unearths century-old mason jar stash filled with pristine heirloom seeds

Few discoveries in a garden carry the quiet electricity of this one. Digging through a neglected corner of a backyard, a ...

Agios Pharmaceuticals, Inc.: U.S. FDA Grants Priority Review to Agios' sNDA for Mitapivat in Sickle Cell Disease

FDA's PDUFA goal date is November 1, 2026If approved, mitapivat is positioned to become the first oral PK activator for patients with sickle cell disease CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIR ...